« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 124, Issue 5
, Pages
1005-1011.e1
, November 2009
Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis
-
Changes in total VAS symptoms in all patients with LAR (left), and between immediate (■) and dual (□) responders (right) after NAPT-grass. Significant differences between baseline and 15 minutes and 1
Changes in total VAS symptoms in all patients with LAR (left), and between immediate (■) and dual (□) responders (right) after NAPT-grass. Significant differences between baseline and 15 minutes and 1, 6, and 24 hours after challenge are indicated by ∗P < .05 and ∗∗P < .001. Significant differences between immediate and dual responders are indicated by +P < .05). Data are expressed as means and SDs.
-
Changes in VOL 2-6cm in all patients with LAR (left), and between immediate (■) and dual (□) responders (right) after NAPT-grass. Significant differences between baseline and 15 minutes and 1, 6, andChanges in VOL 2-6cm in all patients with LAR (left), and between immediate (■) and dual (□) responders (right) after NAPT-grass. Significant differences between baseline and 15 minutes and 1, 6, and 24 hours after challenge are indicated by ∗P < .05 and ∗∗P < .001. Significant differences between immediate and dual responders are indicated by +P < .05. Data are expressed as means and SDs.
-
Nasal levels of tryptase in all patients with LAR (left), and between immediate (■) and dual (□) responders (right) after NAPT-grass. Significant differences between baseline and 15 minutes and 1, 6,Nasal levels of tryptase in all patients with LAR (left), and between immediate (■) and dual (□) responders (right) after NAPT-grass. Significant differences between baseline and 15 minutes and 1, 6, and 24 hours after challenge are indicated by ∗P < .05. Significant differences between immediate and dual responders are indicated by +P < .05. Data are expressed as means and SDs.
-
Nasal levels of ECP in all patients with LAR (left) and between immediate (■) and dual (□) responders (right) after NAPT-grass. Significant differences between baseline and 15 minutes and 1, 6, and 24Nasal levels of ECP in all patients with LAR (left) and between immediate (■) and dual (□) responders (right) after NAPT-grass. Significant differences between baseline and 15 minutes and 1, 6, and 24 hours after challenge are indicated by ∗P < .05. No significant differences between immediate and dual responders were found. Data are expressed as means and SDs.
-
Nasal levels of sIgE in all patients with LAR (left), and between immediate (■) and dual (□) responders (right) after NAPT-grass. Significant differences between baseline and 15 minutes and 1, 6, andNasal levels of sIgE in all patients with LAR (left), and between immediate (■) and dual (□) responders (right) after NAPT-grass. Significant differences between baseline and 15 minutes and 1, 6, and 24 hours after challenge are indicated by ∗P < .05. No significant differences between immediate and dual responders were found. Data are expressed as means and SDs.
-
A-D, Correlation of nasal levels of tryptase (y-axis) with intensity of nasal symptoms (x-axis) after NAPT-grass in patients with LAR: nasal itching (A, Spearman r = 0.788, P = .001), sneezing (B, SpeA-D, Correlation of nasal levels of tryptase (y-axis) with intensity of nasal symptoms (x-axis) after NAPT-grass in patients with LAR: nasal itching (A, Spearman r = 0.788, P = .001), sneezing (B, Spearman r = 0.763, P = .001), rhinorrhea (C, Spearman r = 0.505, P = .001), and nasal obstruction (D, Spearman r = 0.425, P = .003). E, Correlation of nasal levels of ECP with intensity of nasal obstruction after NAPT-grass in patients with LAR (Spearman r = 0.559, P = .001).
This work was supported by grants from Spanish Health Ministry (FIS) (PI081572), “Consejeria de Salud” Andalusia government (PI0181) and FIS network RIRAAF (RD07/0064).
Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.
PII: S0091-6749(09)01086-0
doi: 10.1016/j.jaci.2009.07.018
© 2009 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 124, Issue 5
, Pages
1005-1011.e1
, November 2009
